Please provide your email address to receive an email when new articles are posted on . Compared with methotrexate, systemic therapies for psoriasis either reduced or slightly increased cardiovascular ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an idea of how much the field has changed, clinical guidelines on psoriasis ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. It depends on how much psoriasis someone ...

Patients with psoriasis often have comorbidities that are linked to the systemic inflammation of psoriasis and its treatment, according to study findings published in The Journal of Dermatology. The ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In patients with plaque psoriasis, studies have shown that ...

The initial choice of an oral nonbiologic systemic therapy for patients with psoriasis is often driven by insurance requirements; patients often must try and fail treatment with an older therapy ...

Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis. Half of ...

Older adults with severe or refractory psoriatic disease face a unique challenge: Balancing the need for effective systemic treatment with the increased risk for serious infections. A cohort study ...

Low-grade systemic inflammation, indicated by elevated levels of systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and C-reactive protein (CRP), was associated with a ...

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, inflammation can linger, leading to broader health implications such as obesity ...

The results of 2 recent clinical trials combining the GLP-1 drug and the biologic reinforce the benefits of treating obesity and inflammation together.